|
|
 |
|
Management Biographies |
|
|
 |
|
|
John M. Carroll
Vice President, Global Internal Audits
Schering-Plough Corporation
Kenilworth, New Jersey
John M. Carroll is vice president, Global Internal Audits, for Schering-Plough Corporation. He is responsible for directing the internal auditing activities of the company worldwide.
Carroll joined Schering-Plough in his current position in July 2006. He is a member of the Operations Management Team and an elected officer of the company.
Prior to joining Schering-Plough, Carroll was with American Standard Companies, where he was most recently vice president and general auditor as well as an elected officer. Prior to that, he worked at Bristol-Myers Squibb Company, holding a number of senior finance positions, and with Ernst & Young as a senior manager.
Carroll is a Certified Public Accountant and holds a B.S. degree in accounting
from St. John's University in New York.
Schering-Plough is an innovation-driven, science-centered global health care company. Through its own biopharmaceutical research and collaborations with partners, Schering-Plough creates therapies that help save and improve lives around the world. The company applies its research-and-development platform to human prescription and consumer products as well as to animal health products. Schering-Plough's vision is to "Earn Trust, Every Day" with the doctors, patients, customers and other stakeholders served by its colleagues around the world. The company is based in Kenilworth, N.J., and its Web site is www.schering-plough.com.
|
|
|
 |
|
|
|
|
|
| • |
World Headquarters:
2000 Galloping Hill Road, Kenilworth, N.J. 07033-0530 |
|
| • |
Chairman and CEO:
Fred Hassan |
|
| • |
Number of employees:
55,000 |
|
|
| • |
Net sales (2007):
$12.7 billion |
|
|
| • |
Business operations in more than:
140 countries |
|
| • |
Largest-selling products:
VYTORIN*, ZETIA*, REMICADE, NASONEX. |
|
| • |
R&D investment
(2007):
$2.9 billion |
|
| • |
Areas of research:
cardiovascular disease, central nervous system disorders, immunology and infectious disease, oncology, respiratory diseases and women's health
*VYTORIN and ZETIA are managed through a joint venture with Merck & Co., Inc. Schering-Plough accounts for the joint venture under the Equity method. Total cholesterol joint venture sales were $5.2 billion in 2007.
|
|
|
|
|
 |
|
